BioSpace News Archive

BIONIK Laboratories Corp. today announced that Rich Russo, Chief Financial Officer and Interim Chief Executive Officer, will be presenting a corporate overview and meeting with institutional investors at the Q3 Virtual Investor Summit.

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended June 30, 2022 and provided a corporate update.

ImmPACT Bio USA , Inc. today announced the appointment of Vikram Lamba, M.B.M. as chief financial officer (CFO) and head of business development.

Rubius Therapeutics, Inc. (Nasdaq: RUBY), today reported second quarter 2022 financial results and provided a business update.

AquaBounty Technologies, Inc. (NASDAQ: AQB) (“AquaBounty” or the “Company”), a land-based aquaculture company utilizing technology to enhance productivity and sustainability, today announced the Company’s financial results for the second quarter ended June 30, 2022.

Ferring Pharmaceuticals today announced that the Vaccines and Related Biological Products Advisory Committee will hold a meeting on September 22, 2022, to review data supporting the biologics license application (BLA) for RBX2660, a microbiota-based live biotherapeutic studied for its potential to reduce recurrent C. difficile infection (CDI) after antibiotic treatment.

908 Devices today announces that it has completed the acquisition of privately-held TRACE Analytics GmbH, based in Braunschweig, Germany, a provider of on-line analysis and sampling systems for biotech applications.

ADC Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates.

TransMed7, LLC announced today that the first clinical cases of the final commercial production version of the Sparrow device (a member of the new SpeedBird™ family of vacuum-assisted, Single Insertion / Multiple Collection (SIMC®) Breast Biopsy devices) were successfully performed by Dr. Edgar Staren, a distinguished surgeon and former President of the American Society of Breast Surgeons (ASBrS).

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported financial results for the second quarter ended June 30, 2022 and provided a business update.